文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

晚期头颈部鳞状细胞癌患者血液单核细胞中免疫表型标志物的表达

Expression of immunophenotypic markers in blood mononuclear cells of patients with advanced head and neck squamous cells carcinoma.

作者信息

Silva Adriana Torres da, Vieira Érica Leandro Marciano, Silva Ana Cristina Simões E, Petroianu Andy

机构信息

Universidade Federal de Minas Gerais - Faculty of Medicine - Department of Surgery - Belo Horizonte (MG), Brazil.

出版信息

Acta Cir Bras. 2025 Aug 8;40:e405425. doi: 10.1590/acb405425. eCollection 2025.


DOI:10.1590/acb405425
PMID:40802351
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12333569/
Abstract

PURPOSE: To evaluate peripheral blood mononuclear cells (PBMCs) from patients with advanced head and neck squamous cell carcinoma (HNSCC) in comparison with healthy volunteers, as they can be potential biomarkers. METHODS: Immunophenotyping was performed using flow cytometry of blood mononuclear cells from two groups of adult men: group 1 (n = 14), diagnosed with HNSCC (mouth, larynx, and hypopharynx); and group 2 (n = 14), volunteers, healthy, and without the use of drugs. The cell groups studied were T lymphocytes (CD3, CD4, CD8, CD56 and CD69), B lymphocytes (CD19, CD69), neutrophils (CD11a, CD16, CD66b, HLA-DR), and monocytes (CD14, CD86). RESULTS: In group 1, there were an increase in CD3+CD4+ T lymphocytes (p < 0.001) and NK 56+ cells (p = 0.009) and a decrease in CD3+CD8+ T lymphocytes (p = 0.02) in comparison with group 2. In patients with HNSCC, an increase was found in the expression of the CD69 marker in CD3+CD4+ T lymphocytes (p = 0.03) and CD19+ B lymphocytes (p = 0.01) when compared to healthy volunteers. CONCLUSION: HNSCC triggers a systemic inflammatory response with a decrease in CD8 T cells and an increase in CD4 T and CD56 natural killer cells. CD69 early activation marker was expressed by T and B cells.

摘要

目的:评估晚期头颈部鳞状细胞癌(HNSCC)患者的外周血单个核细胞(PBMC),并与健康志愿者进行比较,因为它们可能是潜在的生物标志物。 方法:对两组成年男性的血液单个核细胞进行流式细胞术免疫表型分析:第1组(n = 14),诊断为HNSCC(口腔、喉和下咽);第2组(n = 14),志愿者,健康且未使用药物。研究的细胞组包括T淋巴细胞(CD3、CD4、CD8、CD56和CD69)、B淋巴细胞(CD19、CD69)、中性粒细胞(CD11a、CD16、CD66b、HLA - DR)和单核细胞(CD14、CD86)。 结果:与第2组相比,第1组中CD3 + CD4 + T淋巴细胞增加(p < 0.001),NK 56 +细胞增加(p = 0.009),CD3 + CD8 + T淋巴细胞减少(p = 0.02)。与健康志愿者相比,HNSCC患者的CD3 + CD4 + T淋巴细胞(p = 0.03)和CD19 + B淋巴细胞(p = 0.01)中CD69标志物的表达增加。 结论:HNSCC引发全身炎症反应,导致CD8 T细胞减少,CD4 T细胞和CD56自然杀伤细胞增加。T细胞和B细胞表达CD69早期激活标志物。

相似文献

[1]
Expression of immunophenotypic markers in blood mononuclear cells of patients with advanced head and neck squamous cells carcinoma.

Acta Cir Bras. 2025-8-8

[2]
Peripheral immune and inflammatory markers as predictors of neoadjuvant immunotherapy response in head and neck squamous cell carcinoma.

Ann Med. 2025-12

[3]
Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment.

Clin Exp Rheumatol. 2025-7

[4]
Cytofluorimetric analysis of mitogen-activated peripheral blood lymphocytes of non-leukemic lymphoma patients reveals an abnormal disease-related expression pattern of activation antigens.

J Cancer Res Clin Oncol. 1990

[5]
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.

J Immunother Cancer. 2025-7-23

[6]
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.

J Cancer Res Clin Oncol. 2023-8

[7]
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.

J Immunother Cancer. 2022-6

[8]
Spectral cytometry of rheumatoid arthritis patients implicates myeloid dendritic cells and granular HLA-DR+CD15+CD16+ cells in pro-inflammatory antigen presentation.

Front Immunol. 2025-7-9

[9]
Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in nonsegmental vitiligo.

Br J Dermatol. 2025-6-20

[10]
Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study.

Cancer Immunol Immunother. 2025-2-11

本文引用的文献

[1]
Regulatory T-cells activated in metastatic draining lymph nodes possibly suppress cancer immunity in cancer tissues of head and neck squamous cell cancer.

Pathol Int. 2024-6

[2]
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer.

Biomedicines. 2024-4-5

[3]
Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.

Front Oncol. 2024-3-7

[4]
Smoking changes adaptive immunity with persistent effects.

Nature. 2024-2

[5]
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer.

Immunotargets Ther. 2024-1-9

[6]
The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.

Biomed Pharmacother. 2024-2

[7]
CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes.

Cancer Immunol Res. 2023-8-3

[8]
Editorial: Genomics, proteomics and immunological signatures as diagnostic, predictive, and prognostic biomarkers in head and neck cancers.

Front Immunol. 2023-1-25

[9]
Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.

BMC Immunol. 2022-11-15

[10]
Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells.

Transl Oncol. 2022-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索